Cervical cancer patients with a pretherapy level of ApoC-II ≤25.8 μg/ml have shorter pelvic progression-free survival (PPFS) than those with a pretherapy level of ApoC-II >25.8 μg/ml (Harima et al., 2021), which indicates that ApoC-II can be a useful biomarker for patients with cervical cancer to predict prognosis and assist clinicians in choosing a better regimen, which ensures the best effect of treatment. The gene discussed is APOC2; the disease is cervical carcinoma.